Wave Life Sciences (WVE) EBT (2014 - 2026)

Wave Life Sciences (WVE) has 13 years of EBT data on file, last reported at -$69.4 million in Q2 2026.

• Quarterly EBT fell 37.42% year-over-year to -$69.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$202.5 million (down 55.9% YoY) and the FY2025 annual result came in at -$204.4 million, down 110.68% from the prior year.
• EBT eased to -$69.4 million in Q2 2026, from -$26.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of $29.3 million in Q4 2024 to a low of -$69.4 million in Q2 2026.
• A 5-year average of -$34.2 million and a median of -$38.4 million in 2022 frame the typical range for EBT.
• The widest YoY moves for EBT: up 279.95% in 2024, down 1039.62% in 2024.
• Tracing WVE's EBT over 5 years: stood at -$43.0 million in 2022, then jumped by 62.22% to -$16.3 million in 2023, then jumped by 279.95% to $29.3 million in 2024, then slumped by 281.79% to -$53.2 million in 2025, then plunged by 30.42% to -$69.4 million in 2026.
• The last three EBT figures came in at -$69.4 million (Q2 2026), -$26.1 million (Q1 2026), and -$53.2 million (Q4 2025), per Business Quant data.